Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 nov. 2024 09h00 HE | Source: Vilya, Inc.

Vilya Announces Exclusive License Agreement of RFdiffusion-based Generative Model from the University of Washington for the Design of Macrocyclic Peptides

– License of proprietary RFdiffusion-based model, RFpeptides, provides Vilya with another powerful structure prediction framework for rapid and unique design of potent and selective macrocycles for...
04 juin 2024 09h00 HE | Source: Vilya, Inc.

Vilya Expands Series A Financing to $71 Million to Advance Computational Drug Design and Develop a New Class of Medicines

Founder and lead investor ARCH Venture Partners is joined by NVIDIA’s NVentures, Menlo Ventures, and MadronaFunding accelerates advancement of Vilya's proprietary computational drug design and...
25 avr. 2024 14h00 HE | Source: Vilya, Inc.

Vilya Announces New Publication in Science Validating Foundational Approach to Design of Novel Chemically Diverse Macrocycles

– Company creating de novo designed macrocycles with enhanced efficacy that precisely target disease biology – Vilya’s privileged macrocycles have the potential to be applied across broad...